期刊
OPEN FORUM INFECTIOUS DISEASES
卷 9, 期 7, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac283
关键词
COVID-19; immunocompromised hosts; monoclonal antibodies; transplant infectious diseases
资金
- Mayo Clinic
- Mayo Clinic Department of Medicine Catalyst Award for Advancing in Academics
This study reports the clinical characteristics of patients who developed COVID-19 shortly after receiving Tixagevimab-cilgavimab, highlighting the need for additional measures to prevent COVID-19 during periods of high transmission of the SARS-CoV-2 virus.
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据